Chapters

Transcript

Video

Although no biomarkers have yet been identified to predict optimal patient cohorts of nemvaleukin-based immunotherapy, do you envision a pathway to identifying biomarkers in the future?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

Ulka Vaishampayan, MBBS

Ulka Vaishampayan, MBBS

Professor of Internal MedicineDirector, Phase I ProgramRogel Cancer CenterUniversity of MichiganAnn Arbor, MI